A Study of Inclisiran in Participants With Renal Impairment Compared to Participants With Normal Renal Function (ORION-7)
A Single-Dose, Open-Label, Parallel-Group Study to Assess the Pharmacokinetics of Inclisiran in Subjects With Renal Impairment Compared to Subjects With Normal Renal Function (ORION-7)
Sponsor: The Medicines Company
Listed as NCT03159416, this PHASE1 trial focuses on Renal Impairment and remains completed. Sponsored by The Medicines Company, it has been updated 8 times since 2017, reflecting limited change activity. This study adds to the evidence base for this therapeutic area through structured, versioned documentation.
Status Flow
Change History
8 versions recorded-
Sep 2024 — Present [monthly]
Completed PHASE1
-
Jul 2024 — Sep 2024 [monthly]
Completed PHASE1
-
Jan 2021 — Jul 2024 [monthly]
Completed PHASE1
-
Dec 2018 — Jan 2021 [monthly]
Completed PHASE1
Status: Active Not Recruiting → Completed
-
Jun 2018 — Dec 2018 [monthly]
Active Not Recruiting PHASE1
▶ Show 3 earlier versions
-
Oct 2017 — Jun 2018 [monthly]
Active Not Recruiting PHASE1
Status: Recruiting → Active Not Recruiting
-
Sep 2017 — Oct 2017 [monthly]
Recruiting PHASE1
Status: Not Yet Recruiting → Recruiting
-
Jun 2017 — Sep 2017 [monthly]
Not Yet Recruiting PHASE1
First recorded
Eligibility Summary
No eligibility information available.
Contact Information
- The Medicines Company
For direct contact, visit the study record on ClinicalTrials.gov .